Vaderis raises $152 million Series B to launch Phase 3 trial for rare vascular disease

Vaderis Therapeutics announced it has closed an oversubscribed $152 million Series B round to fund its AKT inhibitor program.

The capital will support a newly launched Phase 3 study of the oral drug engasertib in patients with hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder affecting about 1 in 3,800 people.

HHT currently has no approved therapies and causes frequent nosebleeds, mucosal bleeding and anemia due to fragile blood vessels. Vaderis aims to be first to market.

The financing was led by Goldman Sachs Alternatives and TCGX, with participation from Omega Funds and EQT Life Sci, and some proceeds will be reserved for regulatory filings with the FDA and other agencies.